Inactive Instrument

News Ocera Therapeutics Inc

Equities

US67552A1088

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®	17-10-20	GL
Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017	17-08-23	GL
Ocera Therapeutics Reports Second Quarter 2017 Financial Results	17-08-01	GL
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis	17-06-01	GL
Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2	17-05-26	GL
Ocera Therapeutics : Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics	17-05-10	PR
Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update	17-05-09	GL
Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017	17-05-03	GL
Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)	17-04-12	GL
Ocera to Present at the 16th Annual Needham Healthcare Conference	17-03-27	GL
Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update	17-03-10	GL
Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy	17-03-08	GL
Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference	17-02-28	GL
Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy	17-01-30	GL
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis	17-01-05	GL
Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy	16-12-07	GL
Ocera to Present at the Stifel 2016 Healthcare Conference	16-11-09	GL
Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update	16-11-02	GL
Ocera Therapeutics : Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors	16-10-28	PU
Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors	16-10-28	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ocera Therapeutics Inc

Equities

US67552A1088

Summary

Filters